Rifampicin: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
m (Protected "Rifampicin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(No difference)

Revision as of 19:08, 27 September 2011

Rifampicin
Clinical data
Pregnancy
category
  • AU: C
Routes of
administration
Oral, IV
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability90 to 95%
MetabolismHepatic and intestinal wall
Elimination half-life6 to 7 hours
Excretion15 to 30% renal
60% faecal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC43H58N4O12
Molar mass822.94 g/mol

WikiDoc Resources for Rifampicin

Articles

Most recent articles on Rifampicin

Most cited articles on Rifampicin

Review articles on Rifampicin

Articles on Rifampicin in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Rifampicin

Images of Rifampicin

Photos of Rifampicin

Podcasts & MP3s on Rifampicin

Videos on Rifampicin

Evidence Based Medicine

Cochrane Collaboration on Rifampicin

Bandolier on Rifampicin

TRIP on Rifampicin

Clinical Trials

Ongoing Trials on Rifampicin at Clinical Trials.gov

Trial results on Rifampicin

Clinical Trials on Rifampicin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Rifampicin

NICE Guidance on Rifampicin

NHS PRODIGY Guidance

FDA on Rifampicin

CDC on Rifampicin

Books

Books on Rifampicin

News

Rifampicin in the news

Be alerted to news on Rifampicin

News trends on Rifampicin

Commentary

Blogs on Rifampicin

Definitions

Definitions of Rifampicin

Patient Resources / Community

Patient resources on Rifampicin

Discussion groups on Rifampicin

Patient Handouts on Rifampicin

Directions to Hospitals Treating Rifampicin

Risk calculators and risk factors for Rifampicin

Healthcare Provider Resources

Symptoms of Rifampicin

Causes & Risk Factors for Rifampicin

Diagnostic studies for Rifampicin

Treatment of Rifampicin

Continuing Medical Education (CME)

CME Programs on Rifampicin

International

Rifampicin en Espanol

Rifampicin en Francais

Business

Rifampicin in the Marketplace

Patents on Rifampicin

Experimental / Informatics

List of terms related to Rifampicin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Rifampicin (INN) (IPA: Template:IPA) or rifampin (USAN) is a bactericidal[1] antibiotic drug of the rifamycin group. It is a semisynthetic compound derived from Amycolatopsis rifamycinica (formerly known as Amycolatopsis mediterranei and Streptomyces mediterranei). Rifampicin may be abbreviated RIF, RMP, RD, RA or R.

Indications

Rifampicin is typically used to treat Mycobacterium infections, including tuberculosis and leprosy; and also has a role in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) in combination with fusidic acid. It is used in prophylactic therapy against Neisseria meningitidis (meningococcal) infection.

It is also used to treat infection by Listeria species, Neisseria gonorrhoeae, Haemophilus influenzae and Legionella pneumophila. For these non-standard indications, sensitivity testing should be done (if possible) before starting rifampicin therapy. Rifampicin resistance develops quickly during treatment and rifampicin monotherapy should not be used to treat these infections — it should be used in combination with other antibiotics. With multidrug therapy (MDT) used as the standard treatment of leprosy, rifampicin is always used in combination with dapsone and clofazimine.

Enterobacteriaceae, Acinetobacter and Pseudomonas species are intrinsically resistant to rifampicin.

Mechanism of action

Rifampicin inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription of messenger RNA (mRNA) and subsequent translation to proteins. Its lipophilic nature makes it a good candidate to treat the meningitis form of tuberculosis, which requires distribution to the central nervous system and penetration through the blood-brain barrier.

Adverse effects

Adverse effects are chiefly related to the drug's hepatotoxicity, and patients receiving rifampicin often undergo liver function tests including aspartate aminotransferase (AST).

The most common unwanted effects are fever, gastrointestinal disturbances, rashes and immunological reactions. Liver damage, associated with jaundice, has also been reported and in some rare cases has led to death.

Taking rifampicin can cause certain bodily fluids, such as urine and tears, to become orange-red in color, a benign but sometimes frightening side-effect. This may permanently stain soft contact lenses. It also may be excreted in breast milk, therefore breast feeding should be avoided.

Rifampicin is a potent inducer of hepatic cytochrome P450 enzymes (such as CYP2D6 and CYP3A4) and will increase the metabolism of many drugs that are cleared by the liver through this enzyme system. This results in numerous drug interactions such as reduced efficacy of hormonal contraception.

Preparations

In the U.S., rifampin is marketed as

In the UK, rifampicin is marketed as

  • Rifadin (Aventis),
  • Rimactane (Sandoz),
  • Rifater (in combination with isoniazid and pyrazinamide) (Aventis),
  • Rifinah (in combination with isoniazid) (Aventis)
  • Rimactazid (in combination with isoniazid) (Sandoz)

In Romania it is marketed as Sinerdol by Sicomed.

In Bulgaria it is marketed as Tubocin by Actavis/Balkanpharma.

References

  1. Trevor A, Katzung B, Masters S (2004). Katzung and Trevor's Pharmacology. McGraw-Hill. ISBN 0-07-142290-0.

Template:SIB

Template:WH Template:WS